ArticleBMC pulmonary medicine2025
Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02609776 (A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is limited data on the unmet needs of advanced non-small cell lung cancer (aNSCLC) patients with epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) in China. The single-arm CHRYSALIS study (NCT02609776) demonstrated durable responses of amivantamab monotherapy among aNSCLC patients with EGFR exon20ins after platinum-based chemotherapy. We aimed to leverage real-world data to describe the unmet needs of these patients and explore the clinical benefits of amivantamab monotherapy through indirect comparison to an external control (EC) from China. MATERIALS AND
methodsEligible patients with any systemic anti-cancer therapy (SACT) after the aNSCLC diagnosis were identified from the electronic medical records of three tertiary medical institutions. Clinical outcomes and treatment patterns were compared between patients with exon20ins and common EGFR (cEGFR) mutations. Effectiveness comparison, including real-world progression-free survival (rwPFS), real-world time to next therapy (rwTTNT) and real-world objective response rate (rwORR) was conducted between CHRYSALIS patients and the EC. Propensity score weighting was used to adjust the baseline characteristics between two cohorts. Real-world outcomes were compared between two cohorts using weighted Cox proportional hazards regression models.
resultsEGFR exon20ins patients (n = 60) under SACT had significantly shorter median rwPFS (9.36 vs. 12.42 months) and rwTTNT (9.82 vs. 16.49 months) compared to cEGFR patients (n = 753). The majority of first-line treatment for exon20ins patients was platinum-based regimens (n = 52, 86.7%). Patients from CHRYSALIS and EC cohort were included in the analysis at each qualifying line of therapy (n = 114 and n = 87). Amivantamab-treated patients had significantly improved median rwPFS (6.93 vs. 5.62 months; P = 0.0133), rwTTNT (12.16 vs. 6.01 months; P = 0.0024), and significantly higher rwORR (36.8% vs. 1.0%; P < 0.0001) than EC cohort. Real-world overall survival was numerically longer in amivantamab-treated patients (23.13 vs. 11.63 months; P = 0.1911).
conclusionChinese patients with EGFR exon20ins under SACT had poor clinical outcomes comparing to those with common EGFR mutations in the study. The clinical benefit of amivantamab monotherapy for exon20ins patients was demonstrated through comparing to a real-world EC under standard of care. Amivantamab monotherapy may be considered as a potential effective treatment option for the Chinese patients harboring exon20ins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.